Community post

Achaogen's 2019 bankruptcy led to the loss of plazomicin, a promising aminoglycoside. John Rex and Kevin Outterson have analyzed the financial failure of plazomicin and Achaogen, summarizing key findings from a post-mortem study.

Their conclusion: novel antibiotics for small patient populations cannot be successfully commercialized in the current US market.